Abbott Laboratories $ABT Shares Acquired by Ashton Thomas Private Wealth LLC

Ashton Thomas Private Wealth LLC grew its position in Abbott Laboratories (NYSE:ABT – Free Report) by 8.2% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 69,024 shares of the healthcare product maker’s stock after purchasing an additional 5,216 shares during the quarter. Ashton Thomas Private Wealth LLC’s holdings in Abbott Laboratories were worth $6,822,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. CenterBook Partners LP bought a new stake in shares of Abbott Laboratories in the third quarter valued at about $633,000. Asset One Wealth Management LLC lifted its stake in Abbott Laboratories by 21.4% in the third quarter. Asset One Wealth Management LLC now owns 4,457 shares of the healthcare product maker’s stock worth $440,000 after acquiring an additional 787 shares during the period. International Assets Investment Management LLC lifted its stake in Abbott Laboratories by 6.0% in the third quarter. International Assets Investment Management LLC now owns 14,823 shares of the healthcare product maker’s stock worth $1,433,000 after acquiring an additional 839 shares during the period. Heritage Family Offices LLP bought a new position in Abbott Laboratories during the 3rd quarter worth about $216,000. Finally, Calamos Wealth Management LLC grew its holdings in Abbott Laboratories by 3.4% during the 3rd quarter. Calamos Wealth Management LLC now owns 6,430 shares of the healthcare product maker’s stock worth $635,000 after acquiring an additional 211 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling at Abbott Laboratories

In other news, EVP Mary Moreland sold 3,500 shares of the firm’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $116.00, for a total value of $406,000.00. Following the completion of the sale, the executive vice president owned 100,791 shares of the company’s stock, valued at $11,691,756. This trade represents a 3.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.46% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ABT has been the topic of a number of research reports. JPMorgan Chase & Co. cut their target price on shares of Abbott Laboratories from $120.00 to $118.00 and set an “overweight” rating on the stock in a research report on Thursday, October 22nd. Rothschild & Co Redburn raised shares of Abbott Laboratories from a “neutral” rating to a “buy” rating and upped their price target for the stock from $119.00 to $127.00 in a research report on Friday, October 2nd. BTIG Research dropped their price objective on shares of Abbott Laboratories from $134.00 to $125.00 and set a “buy” rating on the stock in a research note on Thursday, October 22nd. Barclays initiated coverage on shares of Abbott Laboratories in a report on Wednesday, October 7th. They set an “overweight” rating and a $120.00 price objective on the stock. Finally, Argus downgraded shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday, October 27th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.32.

Get Our Latest Analysis on ABT

Abbott Laboratories Trading Down 3.2%

NYSE ABT opened at $110.02 on Friday. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $132.02. The company has a 50 day moving average price of $104.04 and a 200 day moving average price of $101.78. The company has a quick ratio of 0.97, a current ratio of 1.45 and a debt-to-equity ratio of 0.57. The firm has a market cap of $190.38 billion, a PE ratio of 41.05, a price-to-earnings-growth ratio of 1.93 and a beta of 0.54.

Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, meeting the consensus estimate of $1.42. Abbott Laboratories had a net margin of 9.75% and a return on equity of 18.04%. The company had revenue of $13.01 billion during the quarter, compared to the consensus estimate of $12.99 billion. During the same period last year, the firm earned $1.30 earnings per share. Abbott Laboratories’s revenue was up 14.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Thursday, October 15th. Abbott Laboratories’s dividend payout ratio is currently 94.03%.

About Abbott Laboratories

(Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings.

Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac.

Featured Articles

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.